FLT3 and acute myeloid leukemia: This pipeline is illustrated for FMS-like tyrosinekinase 3 (FLT3),which was chosen due to its coverage in the scientific literature,including data on drugs with documented off-target bindings.14 FLT3 is mutated in 28% of adult patients with de novo acute myeloid leukemia,15 and belongs to the class III family of receptor tyrosine kinases(RTKs).16 The binding pocket of FLT3 withGilteritinib bound is what we target here (the ATP binding site).Gilteritinib is, therefore, a type I inhibitor.